Pulmonary Rehabilitation in Advanced Lung Cancer Patients During Chemotherapy

2015 ◽  
pp. 57-64 ◽  
Author(s):  
D. Jastrzębski ◽  
M. Maksymiak ◽  
S. Kostorz ◽  
B. Bezubka ◽  
I. Osmanska ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Pulmonary Rehabilitation ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients

scholarly journals Mobile Phone App–Based Pulmonary Rehabilitation for Chemotherapy-Treated Patients With Advanced Lung Cancer: Pilot Study (Preprint)

2018 ◽  
Author(s):  
Sojung Park ◽  
Ji Youn Kim ◽  
Jae Cheol Lee ◽  
Hyeong Ryul Kim ◽  
Seungjae Song ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Exercise Capacity ◽  
Pulmonary Rehabilitation ◽  
Walking Distance ◽  
Advanced Lung Cancer ◽  
Smartphone App ◽  
Symptom Scale ◽  
Lung Cancer Patients ◽  
Scale Scores

BACKGROUND Advanced lung cancer patients often have chronic lung disease with reduced exercise capacities and various symptoms leading to altered quality of life (QoL). No studies have assessed pulmonary rehabilitation (PR) employing a mobile app and an Internet of Things device in advanced lung cancer patients undergoing chemotherapy. OBJECTIVE This study aimed to determine the feasibility and efficacy of smartphone app–based PR on exercise capacity, symptom management, and QoL in patients with advanced lung cancer undergoing chemotherapy. METHODS A total of 100 patients were recruited in a prospective, single-arm intervention study using a smartphone app–based PR program for 12 weeks. Exercise capacity (6-min walking distance, 6MWD), QoL, symptom scale scores, and distress indexes were investigated. RESULTS A total of 90 patients completed the PR program. The most common cause of drop out was hospitalization because of cancer progression. After PR, there was significant improvement in the 6MWD; 380.1 m (SD 74.1) at baseline, 429.1 m (SD 58.6) at 6 weeks (P<.001), and 448.1 m (SD 50.0) at 12 weeks (P<.001). However, the dyspnea scale score showed no significant improvement in the patients overall, but there was a trend for improvement in those with a stable tumor response (P=.07). Role (P=.02), emotional (P<.001), and social functioning (P=.002) scale scores showed significant improvement after PR. Symptom scale scores for fatigue (P<.001), anorexia (P=.047), and diarrhea (P=.01) also showed significant improvement. There was significant improvement in depression (P=.048) and anxiety (P=.01), whereas there was no significant change in QoL (P=.06) and severity of pain (P=.24). CONCLUSIONS Smartphone app–based PR represents an effective and feasible program to improve exercise capacity and to manage symptoms and distress in patients with advanced lung cancer who are undergoing chemotherapy.

TP53 Exon 8 Mutations are Associated with Shorter Survival in Advanced Lung Cancer Patients

2018 ◽  
Author(s):  
Yutao Liu ◽  
Fang Xu ◽  
Yubo Wang ◽  
Qingchen Wu ◽  
Buhai Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients

scholarly journals Association of Brain Metastases With Immune Checkpoint Inhibitors Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Yanning Wang ◽  
Qianning Zhang ◽  
Chuansheng Chen ◽  
Yuxuan Hu ◽  
Liyun Miao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Overall Survival ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients ◽  
Hazard Ratios

BackgroundIn pivotal immunotherapy trials, the efficacy of immune checkpoint inhibitors as treatments for lung cancer patients with brain metastases remains controversial. The aim of this study was to assess the relative efficacy of immunotherapy versus standard systemic therapy in advanced lung cancer patients with and without brain metastases.MethodsSystematic searches of PubMed, Embase, Cochrane database, and conference proceedings up to Aug 6, 2020 without year and language restrictions. The main outcomes were the overall survival in patients with and without brain metastases measured by hazard ratios, and the difference in efficacy between patients with and without brain metastases was measured by ratio of hazard ratios.ResultsNine eligible randomized controlled trials involving 6241 patients (682 [11%] with brain metastases and 5559 [89%] without brain metastases) were included in the analysis. A survival benefit of immunotherapy was observed for both patients with brain metastases (HR, 0.75; 95%CI, 0.53-0.97; P = .026) and patients without brain metastases (HR, 0.75; 95%CI, 0.67-0.83; P &lt;.001). However, patients without brain metastases benefit more from immunotherapy than patients with brain metastases (HR, 1.37; 95%CI, 1.15-1.63; P = .001). Additionally, subgroup analyses indicated that tumor type affect the efficacy of immunotherapy in patients with brain metastases (HR, 1.04 vs 1.54; interaction, P = .041).ConclusionsImmunotherapy can significantly improve overall survival for advanced lung cancer patients with asymptomatic brain metastases, especially in patients with non-small-cell lung cancer, but the magnitude of benefit is brain metastases dependent.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020206597.

scholarly journals Dyadic psychosocial intervention for advanced lung cancer patients and their family caregivers: Results of a randomized pilot trial

Cancer ◽  
2014 ◽  
Vol 121 (1) ◽  
pp. 150-158 ◽  
Author(s):  
Hoda Badr ◽  
Cardinale B. Smith ◽  
Nathan E. Goldstein ◽  
Jorge E. Gomez ◽  
William H. Redd
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Family Caregivers ◽  
Psychosocial Intervention ◽  
Pilot Trial ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document